Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Parkinson’s disease (PD) is the second-leading cause of dementia and is characterized by a progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of intraneuronal α-synuclein-positive inclusions. Therapies to date have been directed to the restoration of the dopamine...
Main Authors: | Alexandre Iarkov, George E. Barreto, J. Alex Grizzell, Valentina Echeverria |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2020.00004/full |
Similar Items
-
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease
by: George E. eBarreto, et al.
Published: (2015-01-01) -
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson’s Disease
by: Alexandre Iarkov, et al.
Published: (2021-09-01) -
Cotinine Plus Krill Oil Decreased Depressive Behavior, and Increased Astrocytes Survival in the Hippocampus of Mice Subjected to Restraint Stress
by: Cristhian Mendoza, et al.
Published: (2018-12-01) -
Nicotinic acetylcholine receptors and learning and memory deficits in Neuroinflammatory diseases
by: Valentina Echeverria, et al.
Published: (2023-05-01) -
Cotinine halts the advance of Alzheimer’s disease-like pathology and associated depressive-like behavior in Tg6799 mice
by: Sagar ePatel, et al.
Published: (2014-07-01)